Nalbuphine for Cough Caused by Idiopathic Pulmonary Fibrosis
AI Summary
The CORAL trial examines nalbuphine extended release for cough related to idiopathic pulmonary fibrosis, where few effective treatments exist. This study combines digital cough monitoring with patient feedback, offering a valuable model for future research into cough management in interstitial lung diseases. This research is significant because it seeks to address a critical unmet need in a condition that severely impacts patients' quality of life, potentially paving the way for better antitussive options.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.